FDA Grants Emergency Authorization To Eli Lilly's COVID Treatment

The video discusses a lab-made antibody treatment for mild to moderate COVID-19 patients, designed to mimic the immune response and prevent severe illness. The FDA has authorized its use for high-risk patients. Challenges include manufacturing and distribution, with initial doses going to hospitals. Infusion centers pose risks due to immunosuppressed patients. Distribution is based on local COVID-19 data. The drug is free, but associated services may incur costs for some patients.

What challenges are mentioned regarding the distribution of the drug?

What will happen to Medicare patients without supplemental coverage regarding the drug?